Alumis Inc. (ALMS)

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis

Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review

Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp

Alumis to Participate in Upcoming September Investor Conferences

Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis eyes late-stage lupus study despite trial miss

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next?